Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.65 |
| ▸ | NPC1 | O15118 | 7/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | TTR | P02766 | 1/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | ELANE | P08246 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13767161 | 0.91 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL5834773 | 0.86 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL3137128 | 0.86 | RAB9A (0.82) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL1675377 | 0.85 | TTR (0.68) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL121966 | 0.82 | TTR (0.72) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL29784233 | 0.82 | TTR (0.72) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL4053590 | 0.81 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL6681494 | 0.81 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL2491306 | 0.81 | MMP2 (0.72) | RAB9ANPC1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL3956805 | 0.80 | NPC1 (0.64) | RAB9ANPC1SMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009080788-A2 | ANTIBACTERIAL AGENTS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080788-A2 | ANTIBACTERIAL AGENTS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2009-07-02 | — | — | WO | disclosed |
| US-7138425-B2 | Phthalimide carboxylic acid derivatives | OXFORD GLYCOSCIENCE (UK) LTD. (GB) | 2006-11-21 | — | — | US | disclosed |
| US-20050203153-A1 | Phthalimide carboxylic acid derivatives | OXFORD GLYCOSCIENCE (UK) LTD. (GB) | 2005-09-15 | — | — | US | disclosed |
| EP-1483261-A1 | PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES | Oxford GlycoSciences (UK) Ltd, Attn: Mary Gadsden (GB) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074516-A1 | PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203153-A1 | Phthalimide carboxylic acid derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, IDH1 | RAB9A 1209/4885NPC1 2102/4885SMN1; SMN2 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.